Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol

American Journal of Ophthalmology

Volumn 126, Issue 3, 1998, Pages 390-399

  Camras, Carl B ^a,r   Wax, Martin B ^b   Ritch, Robert ^c   Weinreb, Robert ^d   Robin, Alan L ^e   Higginbotham, Eve J ^f   Lustgarten, Jacqueline ^g,h   Stewart, William C ⁱ   Sherwood, Mark ^j   Krupin, Theodore ^k   Wilensky, Jacob ^l   Cioffi, George A ^m   Katz, L Jay ⁿ   Schumer, Robert A ^g   Kaufman, Paul L ^o   Minckler, Don ^p   Zimmerman, Thom ^q   Stjernschantz, Johan ^r  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Center in River Edge   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^m DEVERS EYE INSTITUTE   (United States)

ⁿ WILLS EYE HOSPITAL   (United States)

^o UNIVERSITY OF WISCONSIN MADISON   (United States)

^p UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^q UNIVERSITY OF LOUISVILLE   (United States)

^r Pharmacia & Upjohn AB   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST; TIMOLOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA VEIN OCCLUSION; TOPICAL DRUG ADMINISTRATION; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EYE COLOR; FEMALE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SAFETY; TIMOLOL;

EID: 0032169880     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00094-4     Document Type: Article

References (39)

1. Stjernschantz J, Resul B. Phenyl-substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992;17: 691-704.
2. Stjernschantz J. Prostaglandins as ocular hypotensive agents: development of an analogue for glaucoma treatment. In : Samuelsson B, Paoletti R, Ramwell PW, Vane JR, editors. Advances in prostaglandin, thromboxane, and leukotriene research. Volume 23. New York: Raven Press, 1995:63-68.
3. 2α analogue. In: Samuelsson B, Paoletti R, Ramwell PW, Vane JR, editors. Advances in prostaglandin, thromboxane, and leukotriene research. Volume 23. New York: Raven Press, 1995:513-518.
4. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995; 102:1743-1752.
5. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-147.
6. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-137.
7. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of Latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. Arch Ophthalmol 1996;114:929-932.
8. Camras CB, Aim A, Watson P, et al. Latanoprost: a prostaglandin analog for glaucoma therapy: efficacy and safety after one year of treatment in 198 patients. Ophthalmology 1996;103:1916-1924.
9. Strahlman E, Tipping R, Vogel R, the Dorzolamide Dose-Response Study Group. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996;122:183-194.
10. Nagasubramanian S, Hitchings RA, Demailly P, et al. Comparison of apraclonidine and timolol in chronic open-angle glaucoma: a three-month study. Ophthalmology 1993;100:1318-1323.
11. Stewart WC, Laibovitz R, Horwitz B, et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Arch Ophthalmol 1996;114: 938-942.
12. 2-adrenergic Agonists in the medical treatment of glaucoma. Curr Opin Ophthalmol 1994;5(2):76-84.
13. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hyper-tension. Arch Ophthalmol 1997;115:847-852.
14. Becker B, Morton WR. Topical epinephrine in glaucoma suspects. Am J Ophthalmol 1966;62:272-277.
15. Alexander DW, Berson FG, Epstein DL. A clinical trial of timolol and epinephrine in the treatment of primary open-angle glaucoma. Ophthalmology 1988;95:247-251.
16. Hoskins HD, Kass MA. Becker-Shaffer's diagnosis and therapy of the glaucomas, 6th ed. St Louis: CV Mosby, 1989:477.
17. McMahon CD, Shaffer RN, Hoskins HD Jr, et al. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979;88:736-738.
18. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980;87:447-450.
19. Wilson RP, Spaeth GL, Poryzees E. The place of timolol in the practice of ophthalmology. Ophthalmology 1980;87: 451-454.
20. Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345:1604-1606.
21. Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986; 102:606-611.
22. 2α analog, PhXA41 (latanoprost), for glaucoma management. J Lipid Mediat 1993;6:535-543.
23. Eagle RC. Iris pigmentation and pigmented lesions: an ultrastructural study. Trans Am Ophthalmol Soc 1988;88: 581-687.
24. Wilkerson CL, Syed NA, Fisher MR, et al. Melanocytes and Iris color: light microscopic findings. Arch Ophthalmol 1996;114:437-442.
25. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color: electron microscopic findings. Arch Ophthalmol 1996;114:443-447.
26. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997; 41(suppl):S125-S128.
27. Pfeiffer N, Grierson I, Sell E, et al. Morphological evaluation of the iris after treatment with latanoprost. ARVO abstracts. Invest Ophthalmol Vis Sci 1997;38(4,suppl): S244.
28. Camras CB, Zhan GL, Wang YL, et al. Effect of sympathectomy (SX) and prostaglandin (PG) analog (latanoprost) treatment on iris color in pigmented rabbits. ARVO abstracts. Invest Ophthalmol Vis Sci 1995;36(4,suppl): S720.
29. Camras CB, Bito LZ, Parkhede U, et al. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: preliminary results of the USA multicenter trial. In: Krieglstein GK, editor. Glaucoma Update. Volume V. Heidelberg: Kaden Verlag, 1995:205-216.
30. Camras CB. Prostaglandins. In: Ritch R, Krupin T, Shields MB, editors. The glaucomas, 2nd ed. Chapter 69. St Louis: Mosby-Year Book, 1996:1449-1461.
31. Bito LZ. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol 1997;41(suppl):S1-S14.
32. Racz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996;114:268-273.
33. Kjellgren D, Douglas G, Mikelberg FS, et al. The shorttime effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand 1995; 73:233-236.
34. Rulo AH, Greve EL, Geijssen HC, Hoyng PFJ. Reduction of Intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103:1276-1282.
35. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-1304.
36. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111: 1351-1358.
37. Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. In: Samuelsson B, Paoletti R, Ramwell PW, Vane JR, editors. Advances in prostaglandin, thromboxane, and leukotriene research. Volume 23. New York: Raven Press, 1995:519-525.
38. 2α analogue, and timolol in patients with elevated introcular pressure. Br J Ophthalmol 1994; 78:899-902.
39. Aim A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-16.